EU Says Teva, Cephalon Deal Violated Antitrust Rules

Law360, New York (July 17, 2017, 3:41 PM EDT) -- A 2005 deal between Israeli generic-drug maker Teva and its subsidiary Cephalon to keep a generic version of narcolepsy drug Provigil off the market unlawfully restricted competition in Europe, antitrust watchdogs alleged on Monday.

The European Commission announced a statement of objections against the pair over the agreement, alleging that the deal potentially hurt patients and health care providers by depriving them access to a cheaper generic drug. The commission’s complaint centers on the same allegations that led to the Federal Trade Commission's record-setting $1.2 billion...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.